BostonSerapha Bio launched with $230 million built on a Chinese drugmaker’s gene-editing patents.
The deal routes China-originated therapy into a US shell via reverse merger, separating patent origin from the commercial vehicle to skirt US-China decoupling rules.
The therapy targets Alpha-1 Antitrypsin Deficiency, a liver-and-lung disease with no curative treatment.
Sources: STAT